Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 88.28M +106.4% |
| Revenue (ttm) | n/a |
| Net Income | -74.23M |
| EPS | -1.88 |
| Shares Out | 42.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 217,919 |
| Open | 2.160 |
| Previous Close | 2.150 |
| Day's Range | 2.050 - 2.190 |
| 52-Week Range | 1.270 - 3.560 |
| Beta | 1.86 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+458.25%) |
| Earnings Date | Aug 12, 2026 |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ACRV stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 458.25% from the latest price.
News
Acrivon Therapeutics reports Q2 EPS (43c), consensus (50c)
“As we look ahead to the second half of 2026, we remain excited about the continued rapid clinical advancement of our precision medicine pipeline,” said Peter Blume-Jensen, chief executive officer,…
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Acrivon Therapeutics Quarterly report: Q2 2026
Acrivon Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Acrivon Therapeutics Earnings release: Q2 2026
Acrivon Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Acrivon Therapeutics Slides: Corporate presentation
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regime...
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic i...
Acrivon Therapeutics assumed with an Outperform at Oppenheimer
Oppenheimer analyst Jeff Jones assumed coverage of Acrivon Therapeutics (ACRV) with an Outperform rating and $8 price target ahead of important updates later this year from the ACR-368 program. An…
Acrivon Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
ACR-368 demonstrates high response rates in serous endometrial cancer, far surpassing standard care, with rapid trial enrollment and a pivotal interim analysis planned for Q4. The pipeline includes promising assets for lung cancer and AML, supported by a predictive AI-driven platform.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing pr...
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
“2026 is an important catalyst year for Acrivon as we advance our two differentiated, AP3-guided clinical oncology programs towards key data read-outs,” said Peter Blume-Jensen, chief executive office...
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms i...
Acrivon Therapeutics Earnings release: Q1 2026
Acrivon Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Acrivon Therapeutics Quarterly report: Q1 2026
Acrivon Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Acrivon Therapeutics Slides: Corporate presentation
Acrivon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon Therapeutics Proxy statement: Proxy filing
Acrivon Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)
“It’s an exciting time for the company as we build on strong maturing data and clinical momentum,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
Acrivon Therapeutics sees cash runway into 2Q27
As of December 31, 2025, the company had cash, cash equivalents and investments of $118.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second…
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
Acrivon Therapeutics Earnings release: Q4 2025
Acrivon Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Acrivon Therapeutics Annual report: Q4 2025
Acrivon Therapeutics has published its Q4 2025 annual report on March 19, 2026.